Psyence Group

About Psyence Group

This author has not yet filled in any details.
So far Psyence Group has created 72 blog entries.
  • Corporate Updates - Psyence

Psyence Group Corporate Update

2023-08-02T14:35:09+02:00July 12, 2023|Press Releases, Investor Information|

Since Psyence’s corporate update issued in June 2022, the Company has made significant progress in its clinical trial programs and in upgrading its production facility and extraction capabilities. Psyence is executing on its strategy and is pleased to provide an update across the pillars of the business.

  • Psyence Corporate Update

Psyence Group Announces Closing Of Fourth Round Tranche Of Private Placement And Conversion Of Convertible Debt Note

2023-04-04T06:53:49+02:00April 4, 2023|Press Releases, Investor Information|

Psyence is pleased to announce that it has issued 9,043,038 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$1,085,164. This brings the total amount the Company has raised pursuant to the previously announced private placement to CAD $3.04 million ("Aggregate Proceeds").

  • PYSENCE_INGENU_FEATURE_2

Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia

2023-03-21T17:14:12+02:00March 21, 2023|Press Releases, Investor Information, Psychedelic News|

Psyence Australia Pty Ltd, has partnered with iNGENū Pty Ltd (iNGENū) to conduct Psyence’s previously announced clinical trial in palliative care. iNGENū is an Australian based, globally focused Contract Research Organization (CRO) with extensive experience working in the psychedelic pharmaceutical drug development and clinical research industry.

Go to Top